American Society of Hematology

Figure 2

$PFS and OS for patients treated at the MTD for different subgroups. (A) PFS and (B) OS for patients treated with REP at the MTD with high-risk disease (presence of t(4;14), t(14;16), del(17p), and/or ampl(1q) as determined by FISH) vs standard-risk disease. (C) PFS and (D) OS for patients treated with REP at the MTD with disease refractory to both lenalidomide and bortezomib (double-refractory MM) vs disease refractory to only lenalidomide. (E) PFS and (F) OS for patients treated with REP at the MTD with REP directly given after development of lenalidomide-refractory disease vs REP given after at least 1 other line of therapy after the development of lenalidomide-refractory disease. (G) PFS and (H) OS for patients treated with REP at the MTD with <3 vs ≥3 prior lines of therapy.$

PFS and OS for patients treated at the MTD for different subgroups. (A) PFS and (B) OS for patients treated with REP at the MTD with high-risk disease (presence of t(4;14), t(14;16), del(17p), and/or ampl(1q) as determined by FISH) vs standard-risk disease. (C) PFS and (D) OS for patients treated with REP at the MTD with disease refractory to both lenalidomide and bortezomib (double-refractory MM) vs disease refractory to only lenalidomide. (E) PFS and (F) OS for patients treated with REP at the MTD with REP directly given after development of lenalidomide-refractory disease vs REP given after at least 1 other line of therapy after the development of lenalidomide-refractory disease. (G) PFS and (H) OS for patients treated with REP at the MTD with <3 vs ≥3 prior lines of therapy.

This Feature Is Available To Subscribers Only